Jefferies Lifts Numbers on Ulta (ULTA) Post Q3; ‘Numbers Better than Good’
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
ULTA Salon (ULTA) PT Lifted to $185 at Piper Jaffray
December 4, 2015 8:43 AM ESTPiper Jaffray analyst Stephanie Wissink reiterated an Overweight rating and boosted her price target on ULTA Salon (NASDAQ: ULTA) to $185.00 (from $170.00) after strong Q3 results and guidance.
commented, "We are maintaining our Overweight and raising our price objective to $185 ($170 prior). We see potential... More
Ulta (ULTA) PT Raised at Cowen on Strong Q3 Highlighted by Exceptional Traffic
December 4, 2015 6:45 AM ESTCowen reiterated an Outperform rating on ULTA Salon (NASDAQ: ULTA), and raised the price target to $200.00 (from $184.00), following the company's 3Q earnings report. ULTA's brand awareness still remains low vs. peers, creating an oppty to gain a substantial amount of new customers, with... More
After-Hours Stock Movers 12/03: (KBIO) (FIVE) (TRVN) Higher; (ZUMZ) (BKS) (COO) Lower (more...)
December 3, 2015 5:59 PM ESTKaloBios Pharma (NASDAQ: KBIO) 33.8% HIGHER; announced that it has signed an agreement to acquire a benznidazole program for the treatment of Chagas Disease from Savant Neglected Diseases, LLC, a privately-held specialty pharmaceutical company. Under the terms of the agreement, KaloBios will pay an upfront payment of $2 million, plus regulatory milestones and a royalty based on product sales. The transaction is expected to close in the coming weeks. Also announced it has entered definitive agreements with institutional and accredited investors in connection with a private placement, or PIPE... More
Ulta Salon (ULTA) Tops Q3 EPS by 6c, Comps Increased 12.8%
December 3, 2015 4:06 PM ESTUlta Salon (NASDAQ: ULTA) reported Q3 EPS of $1.11, $0.06 better than the analyst estimate of $1.05. Revenue for the quarter came in at $910.7 million versus the consensus estimate of $880 million.
Comparable Sales Increased 12.8%GUIDANCE:
Ulta Salon sees Q4 2015... More
Trading Radar for 12/3: Kroger (KR), Express (EXPR), Dollar General (DG), Ambarella (AMBA) Report
December 2, 2015 2:41 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
7:00am EST
8:30am EST
Initial Claims - Street sees 267kContinuing Claims - Street sees 2.177MEarnings:
Canadian Imperial Bank (NYSE:... More
